Alliance of clinical research sites focusing on kidney disease has expanded

Drug and medical device contract clinical development services provider dedicated to renal research, Frenova Renal Research, has announced that its alliance of investigative sites designed to speed up clinical trial initiation has expanded.

The Frenova Rapid STart Up (F1RST Up) alliance has expanded to now include 55 physician investigators who represent 23 research sites.

“The success of F1RST Up is clear evidence of the value the alliance provides to our sponsor clients, our alliance partners and to other contract research organisations (CROs) we collaborate with,” said Kurt Mussina, general manager of Frenova. “F1RST Up accelerates study start-up by taking a no-nonsense approach to driving low-value administrative and contracting burdens out of the start-up process. This provides our partners and customers with a better start-up experience, equating to much better value.”

The alliance membership includes nephrology practices caring for large numbers of chronic kidney disease (CKD) patients. Leveraging Frenova’s access to proprietary clinical research assets, alliance members can make informed protocol designs and perform highly targeted and efficient patient recruitment efforts.

“We formed this alliance with the leading physician investigators from across Frenova’s network of 260 clinical research sites,” added Christina Kahn, Frenova’s F1RST Up alliance lead. “This is important because it means F1RST Up offers sponsors access to a uniquely concentrated source of both high quality renal research sites and a substantial number of patients.”